LITESPARK-024 part 1: belzutifan plus palbociclib in advanced ccRCC
Автор: VJOncology
Загружено: 2026-03-03
Просмотров: 30
Описание:
David McDermott, MD, Beth Israel Deaconess Medical Center, Boston, MA, discusses part 1 of the Phase I/II LITESPARK-024 trial (NCT05468697) of belzutifan and palbociclib in heavily pretreated advanced clear cell renal cell carcinoma (ccRCC). The dose-escalation phase established a manageable safety profile with no new signals. However, efficacy outcomes did not show clear differentiation compared to historical belzutifan monotherapy data in this biomarker-unselected population. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
